Mitoxantrone
- Generic Name
- Mitoxantrone
- Drug Type
- Small Molecule
- Chemical Formula
- C22H28N4O6
- CAS Number
- 65271-80-9
- Unique Ingredient Identifier
- BZ114NVM5P
- Background
An anthracenedione-derived antineoplastic agent.
- Indication
For the treatment of secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Promyelocytic Leukemia, Hodgkin's Lymphoma, Metastatic Breast Cancer, Non-Hodgkin's Lymphoma (NHL), Progressive Relapsing Multiple Sclerosis, Relapsed Leukemia, Relapsed Lymphomas, Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Hormone refractory, advanced Prostate cancer, Relapsed Hepatocellular carcinoma
- Associated Therapies
- Autologous hematopoietic stem cell transplant
PLM60 for Peripheral T Cell Lymphoma (PTCL)
- First Posted Date
- 2018-06-12
- Last Posted Date
- 2020-10-19
- Lead Sponsor
- Conjupro Biotherapeutics, Inc.
- Registration Number
- NCT03553914
- Locations
- 🇺🇸
Gabrial Cancer Center, Canton, Ohio, United States
🇺🇸Gabrail Cancer Center, Canton, Ohio, United States
Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid Neoplasm
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Biological: Recombinant Granulocyte Colony-Stimulating FactorOther: Laboratory Biomarker Analysis
- First Posted Date
- 2018-05-22
- Last Posted Date
- 2023-08-30
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 66
- Registration Number
- NCT03531918
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Lintuzumab-Ac225 in Combination with Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid Leukemia
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2018-02-22
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- Medical College of Wisconsin
- Target Recruit Count
- 26
- Registration Number
- NCT03441048
- Locations
- 🇺🇸
Froedtert Hospital and the Medical College of Wisconsin, Milwuakee, Wisconsin, United States
Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML
- Conditions
- Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations
- Interventions
- Drug: Placebo Oral Tablet
- First Posted Date
- 2017-08-15
- Last Posted Date
- 2021-04-30
- Lead Sponsor
- Arog Pharmaceuticals, Inc.
- Target Recruit Count
- 322
- Registration Number
- NCT03250338
- Locations
- 🇺🇸
Kansas University, Kansas City, Kansas, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
🇨🇦University of Alberta, Edmonton, Alberta, Canada
A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation
- Conditions
- AML With FLT3 Mutation
- Interventions
- First Posted Date
- 2017-06-09
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 276
- Registration Number
- NCT03182244
- Locations
- 🇨🇳
Site CN123, Huangpu Qu, China
🇨🇳Site CN117, Jinan, China
🇨🇳Site CN133, Lanzhou, China
A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia
- Conditions
- Acute Myeloid LeukemiaMyelodysplastic Syndromes
- Interventions
- Combination Product: ITMHABiological: Stem Cell Transplant
- First Posted Date
- 2017-05-23
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 206
- Registration Number
- NCT03164057
- Locations
- 🇺🇸
Rady Children's Hospital and Health Center, San Diego, California, United States
🇺🇸Children's Hospital of Central California, Madera, California, United States
🇺🇸Children's Hospital of Orange County, Orange, California, United States
Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for Relapsed or Refractory Acute Myeloid Leukemia
- Conditions
- AML
- Interventions
- First Posted Date
- 2017-04-18
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 41
- Registration Number
- NCT03118466
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Massachusetts general Hospital, Boston, Massachusetts, United States
Higher or Lower Dose Cladribine, Cytarabine, and Mitoxantrone in Treating Medically Less Fit Patients With Newly Diagnosed Acute Myeloid Leukemia or Myeloid Neoplasm
- Conditions
- Acute Leukemia of Ambiguous LineageMyeloid NeoplasmAcute Myeloid Leukemia
- Interventions
- Biological: Granulocyte Colony-Stimulating FactorOther: Quality-of-Life AssessmentOther: Questionnaire Administration
- First Posted Date
- 2017-01-06
- Last Posted Date
- 2022-03-08
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 50
- Registration Number
- NCT03012672
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
National Multicenter, Controlled, Single-blind Study With Two Parallel Groups Evaluating the Safety and Efficacy of Sequential Treatment With Mitoxantrone and Interferon Versus Interferon Alone in Patients With Strong Risk of Progression in the Initial Phase of Multiple Sclerosis
- First Posted Date
- 2016-10-18
- Last Posted Date
- 2023-03-29
- Lead Sponsor
- Rennes University Hospital
- Target Recruit Count
- 35
- Registration Number
- NCT02937285
- Locations
- 🇫🇷
CHU Rennes, Rennes, France
Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS
- Conditions
- Mixed Phenotype Acute LeukemiaPreviously Treated Myelodysplastic SyndromeRecurrent Adult Acute Myeloid LeukemiaRecurrent High Risk Myelodysplastic SyndromeRefractory High Risk Myelodysplastic SyndromeRefractory Acute Myeloid LeukemiaUntreated Adult Acute Myeloid Leukemia
- Interventions
- Biological: FilgrastimOther: Laboratory Biomarker Analysis
- First Posted Date
- 2016-09-30
- Last Posted Date
- 2020-03-17
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 28
- Registration Number
- NCT02921061
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.